Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 2
1949 3
1950 2
1951 6
1952 5
1953 5
1954 5
1955 2
1957 2
1958 1
1959 2
1961 1
1962 4
1963 5
1965 1
1967 1
1971 2
1973 2
1987 1
1992 2
1994 1
1995 3
1996 3
1997 1
1998 4
1999 5
2000 8
2001 9
2002 5
2003 4
2004 5
2005 4
2006 8
2007 9
2008 10
2009 7
2010 8
2011 13
2012 4
2013 12
2014 17
2015 11
2016 6
2017 6
2018 7
2019 6
2020 6
2021 11
2022 5
2023 5
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Results by year

Filters applied: . Clear all
Page 1
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts.
Esser S, Brunetta J, Inciarte A, Levy I, D'Arminio Monforte A, Lambert JS, van Welzen B, Teruya K, Boffito M, Liu CE, Altuntas Aydın O, Thorpe D, Heinzkill M, Marongiu A, Cassidy T, Haubrich R, D'Amato L, Robineau O. Esser S, et al. Among authors: haubrich r. HIV Med. 2024 Apr;25(4):440-453. doi: 10.1111/hiv.13593. Epub 2023 Dec 26. HIV Med. 2024. PMID: 38148567
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age.
Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, Berenguer J, D'Antoni ML, Blair C, Chuck SK, Piontkowsky D, Martin H, Haubrich R, McNicholl IR, Gallant J. Maggiolo F, et al. Among authors: haubrich r. HIV Med. 2023 Jan;24(1):27-36. doi: 10.1111/hiv.13319. Epub 2022 May 8. HIV Med. 2023. PMID: 35527425 Free PMC article. Clinical Trial.
Reply to Pandita et al.
Olender SA, Perez KK, Chokkalingam AP, Haubrich RH. Olender SA, et al. Among authors: haubrich rh. Clin Infect Dis. 2021 Jul 15;73(2):357. doi: 10.1093/cid/ciaa1350. Clin Infect Dis. 2021. PMID: 32894754 Free PMC article. No abstract available.
Defining treatment failure in resource-rich settings.
Aldous JL, Haubrich RH. Aldous JL, et al. Among authors: haubrich rh. Curr Opin HIV AIDS. 2009 Nov;4(6):459-66. doi: 10.1097/COH.0b013e328331dea5. Curr Opin HIV AIDS. 2009. PMID: 20048711 Free PMC article. Review.
Impact of pre-adapted HIV transmission.
Carlson JM, Du VY, Pfeifer N, Bansal A, Tan VY, Power K, Brumme CJ, Kreimer A, DeZiel CE, Fusi N, Schaefer M, Brockman MA, Gilmour J, Price MA, Kilembe W, Haubrich R, John M, Mallal S, Shapiro R, Frater J, Harrigan PR, Ndung'u T, Allen S, Heckerman D, Sidney J, Allen TM, Goulder PJ, Brumme ZL, Hunter E, Goepfert PA. Carlson JM, et al. Among authors: haubrich r. Nat Med. 2016 Jun;22(6):606-13. doi: 10.1038/nm.4100. Epub 2016 May 16. Nat Med. 2016. PMID: 27183217 Free PMC article.
Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies.
Fusco D, Malenica I, Günthard HF, Gupta SK, Kurbegov D, Balani B, Olender S, Aberg JA, Telep LE, Tian Y, Blair C, Wu G, Haubrich RH, Wang CY, Chokkalingam AP, Osinusi AO, Wendtner CM, Gottlieb RL. Fusco D, et al. Among authors: haubrich rh. Clin Infect Dis. 2024 Nov 22;79(5):1182-1189. doi: 10.1093/cid/ciae336. Clin Infect Dis. 2024. PMID: 38920297
247 results